VYGR vs. CCCC, EDIT, TSHA, ADPT, ALLO, ALEC, ITOS, LXEO, FATE, and PROK
Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include C4 Therapeutics (CCCC), Editas Medicine (EDIT), Taysha Gene Therapies (TSHA), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Alector (ALEC), iTeos Therapeutics (ITOS), Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), and ProKidney (PROK). These companies are all part of the "biological products, except diagnostic" industry.
Voyager Therapeutics (NASDAQ:VYGR) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
Voyager Therapeutics presently has a consensus target price of $18.00, indicating a potential upside of 113.52%. C4 Therapeutics has a consensus target price of $10.11, indicating a potential upside of 78.01%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Voyager Therapeutics is more favorable than C4 Therapeutics.
Voyager Therapeutics received 354 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 67.32% of users gave Voyager Therapeutics an outperform vote while only 37.88% of users gave C4 Therapeutics an outperform vote.
Voyager Therapeutics has a net margin of -2.56% compared to C4 Therapeutics' net margin of -629.24%. Voyager Therapeutics' return on equity of -1.28% beat C4 Therapeutics' return on equity.
In the previous week, Voyager Therapeutics had 14 more articles in the media than C4 Therapeutics. MarketBeat recorded 26 mentions for Voyager Therapeutics and 12 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.63 beat Voyager Therapeutics' score of 0.35 indicating that C4 Therapeutics is being referred to more favorably in the news media.
Voyager Therapeutics has higher revenue and earnings than C4 Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 4.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 8.0% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Voyager Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.22, meaning that its share price is 222% more volatile than the S&P 500.
Summary
Voyager Therapeutics beats C4 Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Voyager Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Voyager Therapeutics Competitors List
Related Companies and Tools
